Table 1B.
Description of stent and non-stent based femoropopliteal procedures (completed 1-year follow-up).
| All (n = 2910) | Stent Based (n = 1339) | Non-Stent Based (n = 1571) | P-Value | |
|---|---|---|---|---|
| Target vessels | ||||
| Superficial femoral artery | 2582 (88.7%) | 1241 (92.7%) | 1341 (85.4%) | <.001 |
| Ostial | 376 (12.9%) | 185 (13.8%) | 191 (12.1%) | .18 |
| Proximal | 827 (28.4%) | 440 (32.9%) | 387 (24.6%) | <.001 |
| Mid | 858 (29.5%) | 418 (31.2%) | 440 (28.0%) | .06 |
| Distal | 734 (25.2%) | 338 (25.2%) | 396 (25.2%) | .98 |
| Popliteal | 336 (11.6%) | 99 (7.4%) | 237 (15.1%) | <.001 |
| Concurrent intervention | ||||
| Below the knee | 11 (0.4%) | 2 (0.2%) | 9 (0.6%) | .06 |
| Iliac artery | 319 (11.0%) | 148 (11.1%) | 171 (10.9%) | .88 |
| Common iliac artery | 155 (5.3%) | 63 (4.7%) | 92 (5.9%) | .17 |
| External iliac artery | 216 (7.4%) | 105 (7.8%) | 111 (7.1%) | .43 |
| Bilateral iliac artery | 103 (3.5%) | 39 (2.9%) | 64 (4.1%) | .09 |
| Below-the knee run-off vessels (n) | 2.27 ± 0.80 | 2.29 ± 0.80 | 2.26 ± 0.81 | .56 |
| Lesion description | ||||
| Mean lesion length (mm) | 120.9 ± 92.8 | 151.7 ± 94.8 | 105.0 ± 87.6 | <.001 |
| Lesions ≥100 mm in length | 1483 (51.0%) | 782 (58.4%) | 701 (44.6%) | <.001 |
| Lesions ≥200 mm in length | 629 (21.6%) | 347 (25.9%) | 282 (18.0%) | <.001 |
| In-stent restenosis | 498 (17.1%) | 188 (14.0%) | 310 (19.7%) | <.001 |
| Chronic total occlusion | 1487 (51.1%) | 863 (64.5%) | 624 (39.7%) | <.001 |
| Severe calcification | 1302 (44.7%) | 625 (46.7%) | 677 (43.1%) | .05 |
| Diffuse disease | 1787 (61.4%) | 849 (63.4%) | 938 (59.7%) | .04 |
| Treatment | ||||
| Chronic total occlusion crossing device | ||||
| Wire catheter | 1309 (40.1%) | 633 (48.7%) | 676 (34.4%) | <.001 |
| Crossing device | 474 (16.3%) | 271 (20.2%) | 203 (12.9%) | <.001 |
| Re-entry device use | 197 (6.8%) | 142 (10.6%) | 55 (3.5%) | <.001 |
| Plain old balloon angioplasty | 2520 (86.6%) | 1208 (90.2%) | 1312 (83.5%) | <.001 |
| Scoring-balloon angioplasty | 478 (16.4%) | 235 (17.6%) | 243 (15.5%) | .13 |
| Drug-coated balloon | 388 (13.3%) | 121 (9.0%) | 267 (17.0%) | <.001 |
| Atherectomy | 1215 (41.8%) | 343 (25.6%) | 872 (51.5%) | <.001 |
| Stent types | ||||
| Bare-metal stent | – | 836 (62.4%) | – | – |
| Drug-eluting stent | – | 233 (17.4%) | – | – |
| Vascular mimetic stent | – | 257 (19.2%) | – | – |
| Covered stent | – | 129 (9.6%) | – | – |
| Bail-out stenting | – | 110 (8.2%) | – | – |
| Stent length (mm) | 163.99 ± 120.97 | |||
| Number of stents | ||||
| 1 | 636 (47.5%) | |||
| 2 | 347 (25.9%) | |||
| 3 | 236 (17.6%) | |||
| 4 | 55 (4.1%) | |||
| 5 | 29 (2.2%) | |||
| Missing | 36 (2.7%) | |||
| Balloon length (mm) | 149.7 ± 111.4 | 164.5 ± 114.3 | 143.1 ± 109.5 | <.001 |
| Number of balloons | ||||
| 1 | 1441 (49.5%) | 708 (52.9%) | 733 (46.7%) | |
| 2 | 762 (27.0%) | 333 (24.9%) | 429 (27.3%) | |
| 3 | 412 (12.7%) | 201 (15.0%) | 211 (13.4%) | |
| No balloon or unknown | 295 (10.1%) | 198 (12.6%) | 97 (7.24%) | |
| Intravascular ultrasound | 187 (6.4%) | 105 (7.8%) | 82 (5.2%) | .01 |
| Embolic protection device | 751 (25.8%) | 236 (17.6%) | 515 (32.8%) | <.001 |
| Distal filter device | 648 (22.3%) | 180 (13.4%) | 468 (29.8%) | <.001 |
| Embolic protection balloon | 19 (0.7%) | 12 (0.4%) | 7 (0.5%) | .13 |
| Aspiration thrombectomy | 136 (4.7%) | 69 (5.2%) | 67 (4.3%) | .26 |
| Thrombolytic therapy | 235 (8.1%) | 144 (10.8%) | 91 (5.8%) | <.001 |
| Glycoprotein IIb/IIIa | 11 (0.4%) | 7 (0.5%) | 4 (0.3%) | .24 |
| Unfractionated heparin | 2330 (80.1%) | 1117 (83.4%) | 1213 (77.2%) | <.001 |
| Bivalirudin | 273 (9.4%) | 121 (9.0%) | 152 (9.7%) | .56 |
| Medication post intervention | ||||
| Aspirin | 2224 (76.4%) | 1045 (78.0%) | 1179 (75.1%) | .06 |
| Dual-antiplatelet therapy | 706 (24.3%) | 431 (32.2%) | 275 (17.5%) | <.001 |
| Clopidogrel | 861 (29.6%) | 505 (37.7%) | 356 (22.7%) | <.001 |
| Anticoagulation therapy | 51 (1.8%) | 24 (1.8%) | 27 (1.7%) | .88 |
| Warfarin | 33 (1.1%) | 15 (1.1%) | 18 (1.2%) | .95 |
| Cilastazol | 28 (10.0%) | 13 (10.0%) | 15 (0.9%) | .96 |
| Lipid-lowering therapy | 1889 (64.9%) | 899 (67.1%) | 990 (63.0%) | .02 |
| ACEI/ARB | 1282 (44.1%) | 626 (46.8%) | 656 (41.8%) | <.01 |
| Beta-blockers | 1349 (46.3%) | 649 (48.5%) | 700 (44.6%) | .04 |
Data presented as mean ± standard deviation or number (%).
Stent-based and non-stent procedures completed 1-year follow-up. P-values based on Chi-square statistics. ACEI/ARB = angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers.